-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Raised to $44 at Mizuho
-
-
-
-
-
-
-
Corbus receives FDA alignment on registration path for cancer drug CRB-701
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) Ahead of Event
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)
-
-
-
-
-
-
-
William Blair Starts Corbus Pharmaceuticals (CRBP) at Outperform
-
-
-
-
-
-
-
Corbus Pharma (CRBP) Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)
-
443,397 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

